É. Fressinaud

发表

Incidence of Factor VIII Inhibitor Development in Severe Hemophilia A Patients Treated only with One Brand of Highly Purified Plasma-Derived Concentrate

C. Rothschild, M. Bertrand, C. Négrier, 1995, Thrombosis and Haemostasis.

French Previously Untreated Patients with Severe Hemophilia A after Exposure to Recombinant Factor VIII : Incidence of Inhibitor and Evaluation of Immune Tolerance

P. Moreau, C. Rothschild, J. Goudemand, 1998, Thrombosis and Haemostasis.

Mutations C1157F and C1234W of von Willebrand factor cause intracellular retention with defective multimerization and secretion

É. Fressinaud, C. Mazurier, D. Meyer, 2006, Journal of thrombosis and haemostasis : JTH.

Facteur Willebrand et maladie de Willebrand : prérequis au diagnostic

É. Fressinaud, 2014 .

Expression of 14 von Willebrand factor mutations identified in patients with type 1 von Willebrand disease from the MCMDM‐1VWD study

J. Goudemand, S. Lethagen, J. Eikenboom, 2009, Journal of Thrombosis and Haemostasis.

Variations in glycosylation of von Willebrand factor with O-linked sialylated T antigen are associated with its plasma levels.

P. D. de Groot, P. Lenting, C. Denis, 2007, Blood.

A new mutation, S1285F, within the A1 loop of von Willebrand factor induces a conformational change in A1 loop with abnormal binding to platelet GPIb and botrocetin causing type 2M von Willebrand disease

J. Lavergne, É. Fressinaud, C. Mazurier, 2003, British journal of haematology.

Identification of a New Type 2M von Willebrand Disease Mutation also at Position 1324 of von Willebrand Factor

É. Fressinaud, C. Mazurier, D. Meyer, 2002, Thrombosis and Haemostasis.

The arginine-552-cysteine (R1315C) mutation within the A1 loop of von Willebrand factor induces an abnormal folding with a loss of function resulting in type 2A-like phenotype of von Willebrand disease: study of 10 patients and mutated recombinant von Willebrand factor.

J. Goudemand, J. Lavergne, É. Fressinaud, 2001, Blood.

von Willebrand factor-mediated platelet adhesion to collagen involves platelet membrane glycoprotein IIb-IIIa as well as glycoprotein Ib.

D. Baruch, É. Fressinaud, K. Sakariassen, 1988, The Journal of laboratory and clinical medicine.

New variant of von Willebrand disease with defective binding to factor VIII.

C. Rothschild, É. Fressinaud, D. Meyer, 1989, Blood.

SYNTHETIC RGD-CONTAINING PEPTIDES OF VON WILLEBRAND FACTOR INHIBIT PLATELET ADHESION TO COLLAGEN

É. Fressinaud, D. Meyer, J. Sadler, 1987, Thrombosis and Haemostasis.

von Willebrand factor and platelet interactions with the vessel wall.

É. Fressinaud, D. Meyer, 1991, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Platelet function analyser (PFA‐100) results and von Willebrand factor deficiency: a 16‐year ‘real‐world’ experience

L. Ardillon, M. Trossaërt, P. Boisseau, 2015, Haemophilia : the official journal of the World Federation of Hemophilia.

Scott syndrome: an inherited defect of the procoagulant activity of platelets.

J. Freyssinet, É. Fressinaud, D. Meyer, 1997, Platelets.

Scott syndrome, characterized by impaired transmembrane migration of procoagulant phosphatidylserine and hemorrhagic complications, is an inherited disorder.

J. Freyssinet, É. Fressinaud, D. Meyer, 1996, Blood.

Role of von Willebrand Factor in Platelet Vessel‐Wall Interactions

É. Fressinaud, K. Sakariassen, D. Meyer, 1987, Annals of the New York Academy of Sciences.

Type 2N von Willebrand disease: clinical manifestations, pathophysiology, laboratory diagnosis and molecular biology.

J. Goudemand, É. Fressinaud, C. Mazurier, 2001, Best practice & research. Clinical haematology.

Mild hemophilia A with factor VIII assay discrepancy: using thrombin generation assay to assess the bleeding phenotype

M. Trossaërt, P. Boisseau, T. Lecompte, 2008, Journal of thrombosis and haemostasis : JTH.

Shear rate-dependent impairment of thrombus growth on collagen in nonanticoagulated blood from patients with von Willebrand disease and hemophilia A.

C. Rothschild, É. Fressinaud, K. Sakariassen, 1992, Blood.

Platelet Factor 4 Complexed to Heparin Is the Target for Antibodies Generated in Heparin-Induced Thrombocytopenia

J. Amiral, É. Fressinaud, M. Wolf, 1992, Thrombosis and Haemostasis.

Presence of autoantibodies to interleukin-8 or neutrophil-activating peptide-2 in patients with heparin-associated thrombocytopenia.

M. Poncz, M. Alessi, B. Tardy, 1996, Blood.

High incidence of anti‐heparin/platelet factor 4 antibodies after cardiopulmonary bypass surgery

M. Trossaërt, J. Amiral, É. Fressinaud, 1998, British journal of haematology.

A point mutation in the cysteine-rich domain of glycoprotein (GP) IIIa results in the expression of a GPIIb-IIIa (alphaIIbbeta3) integrin receptor locked in a high-affinity state and a Glanzmann thrombasthenia-like phenotype.

P. Nurden, P. Newman, É. Fressinaud, 2001, Blood.

Acquired von Willebrand Syndrome: from Pathophysiology to Management

É. Fressinaud, D. Meyer, A. Veyradier, 2000, Thrombosis and Haemostasis.

Management of dental extractions in patients with bleeding disorders.

M. Trossaërt, É. Fressinaud, B. Piot, 2002, Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics.

Screening for von Willebrand disease with a new analyzer using high shear stress: a study of 60 cases.

É. Fressinaud, D. Meyer, A. Veyradier, 1998, Blood.

Type 2 von Willebrand disease causing defective von Willebrand factor-dependent platelet function.

J. Lavergne, É. Fressinaud, C. Mazurier, 2001, Best practice & research. Clinical haematology.

Two novel mutations, Q1053H and C1060R, located in the D3 domain of von Willebrand factor, are responsible for decreased FVIII‐binding capacity

R. Favier, J. Goudemand, É. Fressinaud, 2003, British journal of haematology.

First identification and expression of a type 2N von Willebrand disease mutation (E1078K) located in exon 25 of von Willebrand factor gene

R. d'Oiron, É. Fressinaud, C. Mazurier, 2004, Journal of thrombosis and haemostasis : JTH.

Gene Defects in 150 Unrelated French Cases with Type 2 von Willebrand Disease: from the Patient to the Gene

J. Lavergne, É. Fressinaud, C. Mazurier, 1997, Thrombosis and Haemostasis.

Evaluation of denaturing high‐performance liquid chromatography (DHPLC) in the screening of mutations in hemophilia B patients

M. Trossaërt, P. Boisseau, É. Fressinaud, 2004, Journal of thrombosis and haemostasis : JTH.

Use of Recombinant Factor VIIa in 3 Patients with Inherited Type I Glanzmann’s Thrombasthenia Undergoing Invasive Procedures

P. Nurden, C. Négrier, R. d'Oiron, 2000, Thrombosis and Haemostasis.

Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): results from the European Study MCMDM-1VWD.

A. Tosetto, J. Goudemand, S. Lethagen, 2008, Blood.

Antibodies to Macromolecular Platelet Factor 4-Heparin Complexes in Heparin-induced Thrombocytopenia: a Study of 44 Cases

J. Amiral, É. Fressinaud, M. Wolf, 1995, Thrombosis and Haemostasis.

Nucleotide substitutions at the -6 position in the promoter region of the factor IX gene result in different severity of hemophilia B Leyden: consequences for genetic counseling

M. Vidaud, D. Vidaud, M. Goossens, 1993, Human Genetics.

Aminophospholipid exposure, microvesiculation and abnormal protein tyrosine phosphorylation in the platelets of a patient with Scott syndrome: a study using physiologic agonists and local anaesthetics

J. Freyssinet, É. Fressinaud, A. Nurden, 1997, British journal of haematology.

Molecular basis of severe factor XI deficiency in seven families from the west of France. Seven novel mutations, including an ancient Q88X mutation

M. Trossaërt, É. Fressinaud, M. Trossaert, 2004, Journal of thrombosis and haemostasis : JTH.

Protein A Sepharose immunoadsorption can restore the efficacy of platelet concentrates in patients with Glanzmann's thrombasthenia and anti‐glycoprotein IIb–IIIa antibodies

T. Lambert, B. Guillet, B. Charpentier, 2002, British journal of haematology.

Use of recombinant factor VIIa (NovoSeven) in patients with Glanzmann thrombasthenia.

D. S. Houston, M. Morfini, M. Torchet, 2001, Seminars in hematology.

Significance of capacitative Ca2+ entry in the regulation of phosphatidylserine expression at the surface of stimulated cells.

J. Freyssinet, É. Fressinaud, M. C. Martínez, 1999, Biochemistry.

von Willebrand factor ristocetin cofactor activity correlates with platelet function in a high shear stress system.

É. Fressinaud, D. Meyer, A. Veyradier, 2000, Thrombosis and haemostasis.

Therapeutic monitoring of von Willebrand disease: interest and limits of a platelet function analyser at high shear rates

É. Fressinaud, D. Meyer, A. Veyradier, 1999, British journal of haematology.

The role of platelet von Willebrand factor in platelet adhesion and thrombus formation: a study of 34 patients with various subtypes of type I von Willebrand disease

P. Mannucci, C. Rothschild, F. Rodeghiero, 1994, British journal of haematology.

Willebrand Factor and Ristocetin II. RELATIONSHIP BETWEEN WILLEBRAND FACTOR, WILLEBRAND ANTIGEN AND FACTOR‐VIII ACTIVITY

É. Fressinaud, D. Meyer, C. Jenkins, 1974, British journal of haematology.

is an inherited disorder of procoagulant phosphatidylserine and hemorrhagic complications, Scott syndrome, characterized by impaired transmembrane migration

J. Freyssinet, É. Fressinaud, D. Meyer, 2011 .

Mediation of platelet adhesion to fibrillar collagen in flowing blood by a proteolytic fragment of human von Willebrand factor.

É. Fressinaud, K. Sakariassen, D. Meyer, 1986, Blood.

von Willebrand factor: structure and function.

É. Fressinaud, D. Meyer, J. Girma, 1991, Mayo Clinic proceedings.

Somatic mosaicism and compound heterozygosity in female hemophilia B.

M. Vidaud, I. Laurendeau, D. Vidaud, 2000, Blood.

A novel ELISA-based diagnosis of acquired von Willebrand disease with increased VWF proteolysis

P. Lenting, S. Susen, F. Vincent, 2016, Thrombosis and Haemostasis.

Comparison of Anti‐Human and Anti‐Porcine Factor VIII Inhibitor Levels in 63 Patients with Severe Haemophilia A

M. Torchet, M. Bertrand, B. Boneu, 1993, Vox sanguinis.

von Willebrand factor collagen binding assay with a commercial kit using type III collagen in von Willebrand disease type 2

É. Fressinaud, D. Meyer, A. Veyradier, 2007, Journal of thrombosis and haemostasis : JTH.

Another link between phospholipid transmembrane migration and ABC transporter gene family, inferred from a rare inherited disorder of phosphatidylserine externalization.

J. Mandel, J. Le Pecq, J. Freyssinet, 1997, Biochemical and biophysical research communications.

Intracranial haemorrhages in French haemophilia patients (1991–2001): clinical presentation, management and prognosis factors for death

M. Torchet, H. Chambost, S. Claeyssens, 2005, Haemophilia : the official journal of the World Federation of Hemophilia.

Iliopsoas hematoma in patients with hemophilia: a single-center study.

M. Trossaërt, É. Fressinaud, M. Dauty, 2007, Joint, bone, spine : revue du rhumatisme.

Compliance with Early Long-Term Prophylaxis Guidelines for Severe Hemophilia A.

K. Baumstarck, P. Moreau, T. Lambert, 2021, The Journal of pediatrics.

Compound heterozygosity or heterozygosity with two mutations in cis on the same allele?

J. Goudemand, É. Fressinaud, A. Veyradier, 2011, Haemophilia.

A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM‐1 VWD)

A. Tosetto, J. Goudemand, S. Lethagen, 2006, Journal of thrombosis and haemostasis : JTH.

Validation of the first commercial ELISA for type 2N von Willebrand’s disease diagnosis

J. Goudemand, É. Fressinaud, C. Ternisien, 2011, Haemophilia : the official journal of the World Federation of Hemophilia.

and hemophilia A nonanticoagulated blood from patients with von Willebrand disease Shear rate-dependent impairment of thrombus growth on collagen in

C. Rothschild, É. Fressinaud, D. Meyer, 2011 .

FranceCoag Network: A National Multicenter Prospective Cohort for Congenital Bleeding Disorders.

T. Lambert, É. Fressinaud, V. Guérin, 2005 .

International Survey of Patients with von Willebrand Disease and Angiodysplasia

É. Fressinaud, D. Meyer, 1993, Thrombosis and Haemostasis.

Type 2N von Willebrand disease due to compound heterozygosity for R854Q and a novel R763G mutation at the cleavage site of von Willebrand factor propeptide

P. Nurden, J. Goudemand, É. Fressinaud, 2006, Thrombosis and Haemostasis.

Comparison of Anti-Human and Anti-Porcine Factor Vlll Inhibitor

M. Torchet, M. Bertrand, B. Boneu, 2009 .

Wish-Qol Study - Assessment of Health-Related Quality of Life (HRQoL) and Health-Economic Aspects in Patients with Von Willebrand Disease (VWD) in France: Results of the Women Cohort

A. Borel‐Derlon, D. Desprez, J. Goudemand, 2016 .

Mutations in the A3 domain of von Willebrand factor inducing combined qualitative and quantitative defects in the protein.

C. Casari, P. Legendre, O. Christophe, 2013, Blood.

A Laboratory Phenotype/Genotype Correlation of 1167 French Patients From 670 Families With von Willebrand Disease

C. Denis, S. Susen, A. Borel‐Derlon, 2016, Medicine.

Laboratory diagnosis of von Willebrand disease

É. Fressinaud, D. Meyer, A. Veyradier, 1998, International journal of clinical & laboratory research.

von Willebrand factor mutation promotes thrombocytopathy by inhibiting integrin αIIbβ3.

M. Bryckaert, F. Adam, C. Casari, 2013, The Journal of clinical investigation.

Molecular Genetics of Type 2 von Willebrand Disease

É. Fressinaud, C. Mazurier, D. Meyer, 2002, International journal of hematology.

Expression of two type 2N von Willebrand disease mutations identified in exon 18 of von Willebrand factor gene

É. Fressinaud, C. Mazurier, S. Jorieux, 2004, British journal of haematology.

Defects in type IIA von Willebrand disease: a cysteine 509 to arginine substitution in the mature von Willebrand factor disrupts a disulphide loop involved in the interaction with platelet glycoprotein Ib‐IX

J. Lavergne, É. Fressinaud, B. Bahnak, 1992, British journal of haematology.

Detection of a molecular defect in 40 of 44 patients with haemophilia B by PCR and denaturing gradient gel electrophoresis

M. Vidaud, D. Vidaud, J. Lavergne, 1993, British journal of haematology.

Impaired dimerization of von Willebrand factor subunit due to mutation A2801D in the CK domain results in a recessive type 2A subtype IID von Willebrand disease

É. Fressinaud, C. Mazurier, D. Meyer, 2006, Thrombosis and Haemostasis.

severe thrombocytopenia Impaired megakaryocytopoiesis in type 2B von Willebrand disease with

P. Nurden, W. Vainchenker, N. Debili, 2011 .

Impaired megakaryocytopoiesis in type 2B von Willebrand disease with severe thrombocytopenia.

P. Nurden, W. Vainchenker, N. Debili, 2006, Blood.

proteolytic fragment of human von Willebrand factor Mediation of platelet adhesion to fibrillar collagen in flowing blood by a

É. Fressinaud, D. Meyer, J. Girma, 2011 .

Role of Platelet Membrane Glycoproteins and Von Willebrand Factor in Adhesion of Platelets to Subendothelium and Collagen

É. Fressinaud, H. Baumgartner, K. Sakariassen, 1987, Annals of the New York Academy of Sciences.

A novel platelet-type von Willebrand disease mutation (GP1BA p.Met255Ile) associated with type 2B “Malmö/New York” von Willebrand disease

Renhao Li, C. Gachet, É. Fressinaud, 2016, Thrombosis and Haemostasis.

Molecular misdiagnosis in type 2B von Willebrand disease

S. Bézieau, P. Boisseau, É. Fressinaud, 2006, American journal of hematology.

[Dental extraction in patients with bleeding disorders. Proposal of a protocol based on the type of anesthesia used].

M. Trossaërt, É. Fressinaud, B. Piot, 2003, Revue de stomatologie et de chirurgie maxillo-faciale.

Use of recombinant factor VIIa (NovoSeven) in patients with Glanzmann thrombasthenia.

M. Morfini, M. Torchet, C. Berger, 2001, Seminars in hematology.

Mapping of X-linked myxomatous valvular dystrophy to chromosome Xq28.

J. Trochu, B. Bénichou, F. Kyndt, 1998, American journal of human genetics.

Mapping and Functional Studies of Two Alloantibodies Developed in Patients with Type 3 von Willebrand Disease

A. Houllier, C. Rothschild, É. Fressinaud, 2000, Thrombosis and Haemostasis.

Binding of human von Willebrand factor to collagen and to collagen-stimulated platelets.

C. Rothschild, É. Fressinaud, D. Meyer, 1987, The Journal of laboratory and clinical medicine.

Synthetic RGDS-Containing Peptides of von Willebrand Factor Inhibit Platelet Adhesion to Collagen

É. Fressinaud, D. Meyer, J. Sadler, 1990, Thrombosis and Haemostasis.

Estimation of the von Willebrand Factor-cleaving Protease in Plasma Using Monoclonal Antibodies to vWF

É. Fressinaud, D. Meyer, A. Veyradier, 1999, Thrombosis and Haemostasis.

Conformational changes in the D' domain of von Willebrand factor induced by CYS 25 and CYS 95 mutations lead to factor VIII binding defect and multimeric impairment.

J. Goudemand, É. Fressinaud, C. Mazurier, 2000, Blood.

Hepatitis A in French Hemophiliacs

J. Fonlupt, J. Goudemand, C. Négrier, 1994, Vox sanguinis.

A New Automated Method for von Willebrand Factor Antigen Measurement Using Latex Particles

É. Fressinaud, M. Wolf, D. Meyer, 1999, Thrombosis and Haemostasis.

Platelet von Willebrand factor: evidence for its involvement in platelet adhesion to collagen.

D. Baruch, C. Rothschild, É. Fressinaud, 1987, Blood.

Aurin Tricarboxylic Acid Inhibits Platelet Adhesion to Collagen by Binding to the 509-695 Disulphide Loop of von Willebrand Factor and Competing with Glycoprotein Ib

O. Christophe, É. Fressinaud, D. Meyer, 1992, Thrombosis and Haemostasis.

European Study MCMDM-1VWD phenotype in type 1 von Willebrand disease (VWD): results from the Response to desmopressin is influenced by the genotype and

A. Tosetto, J. Goudemand, S. Lethagen, 2013 .

Clinical, Laboratory, and Molecular Markers of Type 2 von Willebrand Disease

É. Fressinaud, C. Mazurier, D. Meyer, 2011 .

An unexpected transmission of von Willebrand disease type 3: the first case of maternal uniparental disomy 12

S. Bézieau, P. Boisseau, É. Fressinaud, 2011, Haematologica.

von Willebrand factor mutation promotes thrombocytopathy by inhibiting integrin a IIb b 3

M. Bryckaert, F. Adam, C. Casari, 2018 .

[Increase in the frequency of heparin-induced thrombopenia as a result of improved case-finding].

É. Fressinaud, P. Allain, P. Lainé-Cessac, 1987, Therapie.

Assessment of the Expression of Candidate Human Plasma Membrane Phospholipid Scramblase in Scott Syndrome Cells

N. Janel, J. Freyssinet, É. Fressinaud, 1999, Thrombosis and Haemostasis.

Mutational analysis of the von Willebrand factor gene in type 1 von Willebrand disease using conformation sensitive gel electrophoresis: a comparison of fluorescent and manual techniques.

J. Goudemand, J. Eikenboom, J. Batlle, 2007, Haematologica.

Platelet von Willebrand factor: evidence for its involvement in platelet adhesion to collagen.

D. Baruch, É. Fressinaud, H. Baumgartner, 1987, Blood.

Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): results from the European Study MCMDM-1VWD.

A. Tosetto, J. Goudemand, S. Lethagen, 2008, Blood.

Mutations in the A3 domain of von Willebrand factor inducing combined qualitative and quantitative defects in the protein.

C. Casari, P. Legendre, O. Christophe, 2013, Blood.

Clinical, biological and molecular diagnosis

É. Fressinaud, 2014 .

Somatic mosaicism and compound heterozygosity in female hemophilia B

M. Vidaud, I. Laurendeau, D. Vidaud, 2000 .